drugset / Trial / NCT00950534

Effectiveness and Safety of Two Approaches to the Management of Type 2 Diabetes Mellitus in Australian Primary Care

NCT00950534 ↗

Phase 4 Terminated 25 enrolled Sanofi
RandomizedParallel-groupOpen-labelTreatment

Summary

The primary objective is to demonstrate the improvement in glycosylated haemoglobin (HbA1c) levels after general practitioner (GP) initiation and management of type 2 diabetes mellitus (T2DM) with insulin glargine compared with their usual clinical practice. The secondary objective is to demonstrate the importance of GP initiation of insulin glargine for the treatment of T2DM.

Timeline

Start
2009-07
Primary completion
2010-08
Completion
2010-08

Outcome

Outcome not reported

Stopped (Enrollment): “due to poor recruitment”

Drugs

EvaluationDrugModalityDoseRoute
Subject insulin glargine Protein / enzyme biologic — —